Limitations of the present study include a lack of understanding of how APOE drives downstream effects within the brain, especially in the context of hallmark AD/ADRD pathology (e.g., β-amyloid and tau), which is beyond the scope of this investigation. The gene discussed is MAPT; the disease is Alzheimer disease.